Moomoo AI 已提取核心信息
EyePoint Pharmaceuticals officer, DAVID S JONES, is set to sell 38,541 shares of common stock on 01/22/2024, as per the latest filing. The shares, valued at an aggregate market value of $860,235.12, were acquired on the same day through the exercise of stock options directly from the issuer. The transaction involved a cash payment made for the securities. This sale follows a period where no other securities transactions were reported by JONES in the past three months, according to the provided review of securities sold.
EyePoint Pharmaceuticals officer, DAVID S JONES, is set to sell 38,541 shares of common stock on 01/22/2024, as per the latest filing. The shares, valued at an aggregate market value of $860,235.12, were acquired on the same day through the exercise of stock options directly from the issuer. The transaction involved a cash payment made for the securities. This sale follows a period where no other securities transactions were reported by JONES in the past three months, according to the provided review of securities sold.
根据最新文件，EyePoint制药公司高管戴维·琼斯定于2024年1月22日出售38,541股普通股。这些股票的总市值为860,235.12美元，是当天通过直接向发行人行使股票期权收购的。该交易涉及以现金支付证券。根据提供的对已售证券的审查，此次出售是在琼斯在过去三个月中没有报告其他证券交易之后进行的。
根据最新文件，EyePoint制药公司高管戴维·琼斯定于2024年1月22日出售38,541股普通股。这些股票的总市值为860,235.12美元，是当天通过直接向发行人行使股票期权收购的。该交易涉及以现金支付证券。根据提供的对已售证券的审查，此次出售是在琼斯在过去三个月中没有报告其他证券交易之后进行的。
有用
没用
该公告为独立文件：